Poster Spotlight 4: Personalization and De-escalation in Loco Regional Therapy
Session Details
Moderator
Wendy A Woodward, UT MD Anderson Cancer Center, Houston, TX
Presentation numberPS4-2
Long-term efficacy and biological characterisation of ipsilateral breast tumour recurrences after partial versus whole-breast irradiation: the Florence randomised phase 3 trial
Icro Meattini, University of Florence, Florence, Italy
Presentation numberPS4-4
Acute Toxicity of Ultra-hypofractionated Regional Nodal Irradiation including Internal Mammary Nodes for Breast Cancer (ARROW): A Multicenter Phase 2 Trial
Siyue Zheng, Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, China
Presentation numberPS4-5
More Extensive Locoregional Therapy Does Not Confer Survival Benefit in TNBC
Astrid M Botty van den Bruele, Duke University Hospital, Durham, NC
Presentation numberPS4-6
Updates in Radiotherapy Targets and Regimens
Rachel B Jimenez, Mass General Brigham, Boston, MA
Presentation numberPS4-7
Pathologic Nodal Burden Beyond Current Sentinel Lymph Node Biopsy Omission Criteria in cT1N0M0 Breast Cancer
Ji-Jung Jung, Samsung Medical Center, Seoul, Korea, Republic of
Presentation numberPS4-8
Delayed sentinel lymph node biopsy in patients with ductal carcinoma in situ or low-risk invasive breast cancer: A preplanned interim analysis from the SentiNot 2.0 randomised trial.
Andreas Karakatsanis, Uppsala University; Akademiska University Hospital, Uppsala, Sweden
Presentation numberPS4-9
Nanoparticle-assisted axillary staging enables de-escalation of axillary surgery irrespective of post-neoadjuvant chemotherapy clinical nodal status
Ruixian Chen, West China Hospital, Sichuan University, Chengdu, China
Presentation numberPS4-10
Initial Multicenter Results of the Phase III Randomized CRYSTAL-SIX Trial Comparing Cryoablation With Breast Surgery for Early-Stage Breast Cancer
Vanessa Monteiro Sanvido, Hcor Research Institute, São Paulo, Brazil
Presentation numberPS4-11
Preoperative Endocrine Therapy Tolerance and Two-Year Adjuvant Endocrine Therapy Adherence in Older Women With Early-Stage ER-Positive Breast Cancer: Final Analysis of the POWER Trial
Trish Millard, University of Virginia, Charlottesville, VA